+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Proto Oncogene Tyrosine Protein Kinase Src - Drugs In Development, 2021

  • ID: 5359596
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 109 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Avalyn Pharma Inc
  • KeifeRx LLC
  • Taiwan Liposome Co Ltd
  • TopiVert Ltd
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) pipeline Target constitutes close to 20 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Proto Oncogene Tyrosine Protein Kinase Src - Drugs In Development, 2021, outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Proto-oncogene tyrosine-protein kinase Src or proto-oncogene c-Src is a non-receptor tyrosine kinase protein that is encoded by the SRC gene. It participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. It plays a role in the activation of other protein tyrosine kinase (PTK) families. It plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. The molecules developed by companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 3, 7, 1, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Respiratory, Central Nervous System, Gastrointestinal, Genetic Disorders, Infectious Disease, Musculoskeletal Disorders and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Colorectal Cancer, Idiopathic Pulmonary Fibrosis, Ulcerative Colitis, Central Nervous System (CNS) Tumor, Endometrial Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Interstitial Lung Fibrosis, Lymphangioleiomyomatosis, Medullary Thyroid Cancer, Melanoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alcohol Addiction, Anaplastic Large Cell Lymphoma (ALCL), Angiosarcoma, Bladder Cancer, Breast Cancer, Brenner Tumor, Bronchiolitis Obliterans, Cervical Cancer, Coronavirus Disease 2019 (COVID-19) Pneumonia, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Friedreich Ataxia, Gallbladder Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Head and Neck Cancer, Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Disease), Keratoconjunctivitis Sicca (Dry Eye), Lewy Body Dementia, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Malignant Pleural Mesothelioma, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Pancreatic Cancer, Papillary Thyroid Cancer, Parkinson's Disease, Peritoneal Cancer, Pneumoconiosis, Psychosis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Salivary Gland Cancer, Squamous Non-Small Cell Lung Cancer, Thyroid Cancer, Triple-Negative Breast Cancer (TNBC), Unspecified Cancer and Uterine Cancer.

Furthermore, this report also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)
  • The report reviews Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Avalyn Pharma Inc
  • KeifeRx LLC
  • Taiwan Liposome Co Ltd
  • TopiVert Ltd
  • Introduction
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by AbbVie Inc, 2021
  • Pipeline by AstraZeneca Plc, 2021
  • Pipeline by Avalyn Pharma Inc, 2021
  • Pipeline by Boehringer Ingelheim International GmbH, 2021
  • Pipeline by KeifeRx LLC, 2021
  • Pipeline by Lead Discovery Center GmbH, 2021
  • Pipeline by Taiwan Liposome Co Ltd, 2021
  • Pipeline by TopiVert Ltd, 2021
  • Pipeline by Turning Point Therapeutics Inc, 2021
  • Dormant Products, 2021
  • Dormant Products, 2021 (Contd..1)
  • Dormant Products, 2021 (Contd..2)
  • Discontinued Products, 2021
List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
Note: Product cover images may vary from those shown
  • AbbVie Inc
  • AstraZeneca Plc
  • Avalyn Pharma Inc
  • Boehringer Ingelheim International GmbH
  • KeifeRx LLC
  • Lead Discovery Center GmbH
  • Taiwan Liposome Co Ltd
  • TopiVert Ltd
  • Turning Point Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll